TY - JOUR
T1 - Tat toxoid as a component of a preventive vaccine in seronegative subjects
AU - Gringeri, Alessandro
AU - Santagostino, Elena
AU - Muça-Perja, Myrvet
AU - Le Buanec, Helene
AU - Bizzini, Bernard
AU - Lachgar, Abderrhaim
AU - Zagury, Jean Francois
AU - Rappaport, Jay
AU - Burny, Arsene
AU - Gallo, Robert C.
AU - Zagury, Daniel
PY - 1999/4/1
Y1 - 1999/4/1
N2 - Because administration of Tat protein, the HIV-1 toxin that induces immunosuppression and apoptosis, may be deleterious to the host immune system, a chemically inactivated but nonetheless immunogenic Tat preparation, Tat toxoid, was used to immunize seronegative individuals against Tat. In an open, controlled, phase I clinical trial, Tat toxoid turned out to be safe, well tolerated, and able tO trigger a specific immune reaction. In particular, a threefold to more than 10-fold increase of circulating antibodies directed against the native Tat was observed after immunization in all of 5 immunized study subjects, together with a positive reaction to delayed-type hypersensitivity (DTH) skin test with Tat toxoid in vivo and increased lymphoproliferative response to native Tat in vitro. Persistent (≥ year) high levels of circulating anti-Tat antibodies could prevent the Tat- induced immune suppression and, following HIV-1 exposure, allow the anti- HIV-1 cellular immune response, with its early release of protective β- chemokines, to occur leading to an increase of host resistance, that is, protection.
AB - Because administration of Tat protein, the HIV-1 toxin that induces immunosuppression and apoptosis, may be deleterious to the host immune system, a chemically inactivated but nonetheless immunogenic Tat preparation, Tat toxoid, was used to immunize seronegative individuals against Tat. In an open, controlled, phase I clinical trial, Tat toxoid turned out to be safe, well tolerated, and able tO trigger a specific immune reaction. In particular, a threefold to more than 10-fold increase of circulating antibodies directed against the native Tat was observed after immunization in all of 5 immunized study subjects, together with a positive reaction to delayed-type hypersensitivity (DTH) skin test with Tat toxoid in vivo and increased lymphoproliferative response to native Tat in vitro. Persistent (≥ year) high levels of circulating anti-Tat antibodies could prevent the Tat- induced immune suppression and, following HIV-1 exposure, allow the anti- HIV-1 cellular immune response, with its early release of protective β- chemokines, to occur leading to an increase of host resistance, that is, protection.
KW - AIDS vaccine
KW - HIV-1-induced immunosuppression
KW - Tat toxin
KW - Tat toxoid
UR - http://www.scopus.com/inward/record.url?scp=0032997424&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0032997424&partnerID=8YFLogxK
M3 - Article
C2 - 10096581
AN - SCOPUS:0032997424
VL - 20
SP - 371
EP - 375
JO - Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology
JF - Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology
SN - 1077-9450
IS - 4
ER -